Merck Net Profit Margin 2006-2020 | MRK

Current and historical net profit margin for Merck (MRK) from 2006 to 2020. Net profit margin can be defined as net Income as a portion of total sales revenue. Merck net profit margin for the three months ending March 31, 2020 was .
Merck Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2020-03-31 $48.08B $10.15B 21.10%
2019-12-31 $46.84B $9.84B 21.01%
2019-09-30 $45.97B $9.31B 20.26%
2019-06-30 $44.37B $9.36B 21.10%
2019-03-31 $43.07B $8.40B 19.50%
2018-12-31 $42.29B $6.22B 14.71%
2018-09-30 $41.73B $3.35B 8.02%
2018-06-30 $41.26B $1.34B 3.25%
2018-03-31 $40.73B $1.58B 3.88%
2017-12-31 $40.12B $2.39B 5.97%
2017-09-30 $39.80B $2.85B 7.15%
2017-06-30 $40.02B $5.09B 12.71%
2017-03-31 $39.93B $4.35B 10.88%
2016-12-31 $39.81B $3.92B 9.85%
2016-09-30 $39.91B $5.49B 13.76%
2016-06-30 $39.44B $5.13B 13.01%
2016-03-31 $39.39B $4.61B 11.72%
2015-12-31 $39.50B $4.44B 11.25%
2015-09-30 $39.77B $10.78B 27.11%
2015-06-30 $40.25B $9.85B 24.48%
2015-03-31 $41.40B $11.17B 26.98%
2014-12-31 $42.24B $11.92B 28.22%
2014-09-30 $43.08B $5.39B 12.50%
2014-06-30 $43.55B $5.61B 12.89%
2014-03-31 $43.63B $4.52B 10.35%
2013-12-31 $44.03B $4.40B 10.00%
2013-09-30 $44.45B $4.53B 10.19%
2013-06-30 $44.91B $5.14B 11.44%
2013-03-31 $46.21B $6.02B 13.03%
2012-12-31 $47.27B $6.17B 13.04%
2012-09-30 $47.82B $6.76B 14.14%
2012-06-30 $48.36B $6.72B 13.90%
2012-03-31 $48.20B $6.95B 14.42%
2011-12-31 $48.05B $6.26B 13.02%
2011-09-30 $47.85B $4.22B 8.82%
2011-06-30 $46.95B $2.87B 6.12%
2011-03-31 $46.15B $1.60B 3.47%
2010-12-31 $45.99B $0.86B 1.87%
2010-09-30 $43.99B $7.84B 17.82%
2010-06-30 $38.91B $10.92B 28.07%
2010-03-31 $33.47B $11.73B 35.04%
2009-12-31 $27.43B $12.85B 46.86%
2009-09-30 $23.37B $8.03B 34.36%
2009-06-30 $23.26B $5.70B 24.50%
2009-03-31 $23.41B $5.91B 25.24%
2008-12-31 $23.85B $7.79B 32.65%
2008-09-30 $24.06B $4.53B 18.81%
2008-06-30 $24.19B $4.96B 20.50%
2008-03-31 $24.25B $4.87B 20.07%
2007-12-31 $24.20B $3.27B 13.50%
2007-09-30 $24.00B $5.38B 22.42%
2007-06-30 $23.33B $4.80B 20.55%
2007-03-31 $23.00B $4.62B 20.08%
2006-12-31 $22.64B $4.43B 19.59%
2006-09-30 $22.36B $5.08B 22.72%
2006-06-30 $22.36B $5.56B 24.86%
2006-03-31 $22.06B $4.78B 21.68%
2005-12-31 $22.01B $4.63B 21.04%
Sector Industry Market Cap Revenue
Medical Large Cap Pharmaceutical $207.633B $46.840B
Merck & Co., Inc., a leading global biopharmaceutical company known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world's most challenging diseases. Through their prescription medicines, vaccines, biologic therapies and animal health products, they work with customers and operate the countries to deliver innovative health solutions. The Company also demonstrate their commitment to increasing access to health care through far-reaching policies, programs and partnerships. Merck continues to be at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world - including cancer, cardio-metabolic diseases, emerging animal diseases, Alzheimer's disease and infectious diseases including HIV and Ebola.
Stock Name Country Market Cap PE Ratio
Johnson & Johnson (JNJ) United States $388.076B 16.59
Roche Holding AG (RHHBY) Switzerland $294.143B 0.00
Pfizer (PFE) United States $199.918B 12.41
Novartis AG (NVS) Switzerland $196.843B 15.36
Novo Nordisk (NVO) Denmark $151.861B 25.29
Eli Lilly (LLY) United States $142.712B 23.10
AstraZeneca (AZN) United Kingdom $141.323B 29.11
Bristol-Myers Squibb (BMY) United States $138.771B 11.59
AbbVie (ABBV) United States $138.592B 10.18
Sanofi (SNY) $125.457B 14.52
GlaxoSmithKline (GSK) United Kingdom $104.605B 12.49
Bayer (BAYRY) Germany $69.270B 9.88
H Lundbeck (HLUYY) Denmark $8.181B 14.21
Innoviva (INVA) United States $1.408B 8.13